

(19)



(11)

EP 2 061 469 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 2 (W2 B1)

Corrections, see

Bibliography INID code(s) 54

(51) Int Cl.:

A61K 31/517 ^(2006.01) **C07D 239/94** ^(2006.01)

C07C 211/39 ^(2006.01)

(86) International application number:

PCT/US2007/077974

(87) International publication number:

WO 2008/033748 (20.03.2008 Gazette 2008/12)

(48) Corrigendum issued on:

26.02.2014 Bulletin 2014/09

(45) Date of publication and mention
of the grant of the patent:

05.06.2013 Bulletin 2013/23

(21) Application number: **07842114.6**

(22) Date of filing: **10.09.2007**

(54) **QUINAZOLINE BASED EGFR INHIBITORS**

CHINAZOLIN-BASIERTE EGFR-HEMMER

INHIBITEURS D'EGFR À BASE DE QUINAZOLINE

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

Designated Extension States:

AL BA HR MK RS

(30) Priority: **11.09.2006 US 843644 P**

20.03.2007 US 895873 P

(43) Date of publication of application:

27.05.2009 Bulletin 2009/22

(73) Proprietor: **Curis, Inc.**

Lexington, MA 02421 (US)

(72) Inventors:

- **QIAN, Changgeng**
Wayland, MA 01778 (US)
- **CAI, Xiong**
Belmont, MA 02478 (US)

(74) Representative: **Potter Clarkson LLP**

**The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG (GB)**

(56) References cited:

EP-A1- 0 566 226 WO-A2-2005/097134
US-A1- 2004 265 228 US-B1- 6 414 148

EP 2 061 469 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).